Author:
Pezzolo Elena,Gambardella Alessio,Guanti Mario,Bianchelli Tommaso,Bertoldi Alberto,Giacchetti Alfredo,Donini Massino,Argenziano Giuseppe,Naldi Luigi
Reference5 articles.
1. Nomenclature and clinical phenotypes of atopic dermatitis;Girolomoni;Ther Adv Chronic Dis,2021
2. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti–IL-13 mAb;Miron;J Allergy Clin Immunol,2022
3. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2);Wollenberg;Br J Dermatol,2021
4. Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study;Pezzolo;J Eur Acad Dermatol Venereol,2023
5. Licata G, Tancredi V, Pezzolo E, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: a case series. J Eur Acad Dermatol Venereol. Published online April 5, 2023. https://doi.org/10.1111/jdv.19108
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献